类他类药物通过ERK5激活增强肝炎C病毒颗粒的细胞外释放
Chie Aoki-Utsubo1, Masanori Kameoka1, Lin Deng2
1Department of Public Health, Graduate School of Health Sciences, Kobe University, Kobe, Japan.
Microbiology and immunology
|July 29, 2024
概括
像洛瓦斯塔丁这样的他类药物通过激活ERK5,独立于病毒复制,显著促进型肝炎病毒 (HCV) 颗粒的释放. 这种效应与HMG-CoA减少酶抑制有关.
科学领域:
- 病毒学 病毒学
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 已知他类药物是3 - 基-3 - 甲基氨酸辅酶A (HMG-CoA) 减少酶的抑制剂.
- 以前的研究表明,他类药物可以适度抑制C型肝炎病毒 (HCV) 复制.
- 型肝炎病毒感染构成了重大的全球健康挑战,需要新的治疗策略.
研究的目的:
- 为了研究高度洛瓦斯塔丁对HCV复制和传染性颗粒释放的影响.
- 阐明细胞外信号调节激酶5 (ERK5) 在以他类药物为媒介的HCV调节中的作用.
- 为了确定其他他类药物是否对HCV病毒释放具有类似的影响.
主要方法:
- 使用C型肝炎病毒细胞培养 (HCVcc) 系统.
- 使用高度的洛瓦斯塔丁 (5-20微克/毫升).
- 评估了病毒RNA复制,蛋白质合成,病毒组合和颗粒释放;用于机械研究使用ERK5抑制剂和小干扰RNA (siRNA);测试了其他他类药物和非抑制类比药物.
主要成果:
- 高度的洛瓦斯塔丁增强了HCV传染性粒子释放的40倍,而不会影响病毒RNA复制,蛋白质合成或组装.
- 洛瓦斯因剂量而异,在受感染和未受感染的细胞中增加了ERK5的酸化 (激活).
- 抑制或淘汰ERK5部分逆转了增强的病毒释放;其他抑制HMG-CoA减少酶的他类药物模仿了洛瓦斯塔丁的作用,而脱水洛瓦斯塔丁没有.
结论:
- 类药物,特别是洛瓦类药物,显著增强了感染细胞中传染性HCV颗粒的释放.
- 这种增强通过抑制HMG-CoA减少酶和随后激活ERK5信号通路来实现.
- 这些发现表明,他类药物通过一种新的机制影响HCV病变,独立于直接抑制病毒复制.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
613
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
613
Cholesterol: Significance and Regulation
524
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
524
Hepatic Drug Excretion: Enterohepatic Cycling
1.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.5K


